EMA Authorised: Aripiprazole Sandoz (aripiprazole) — Sandoz GmbH

View source ↗

Summary

Authorised new aripiprazole product (Sandoz) for schizophrenia and bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Aripiprazole Sandoz (aripiprazole)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Sandoz GmbH. Decision date: 20/08/2026